Fibrin sealants reducing the incidence, extent and severity of anti-adhesion

Haemacure Corporation last month disclosed the apparent clinical utility of its fibrin sealant in the prevention of post-surgical adhesion:

Haemacure Corporation (TSX : HAE), a Montreal-based specialty bio-therapeutics company developing high-value human plasma-derived protein products for commercialization, disclosed today the positive results of a second preclinical study conducted on the use of its proprietary lead product candidate, the human fibrin sealant Hemaseel(R)HMN, in preventing the formation of post-surgical adhesions in a bleeding surgical model.

In two preclinical studies, this utility was demonstrated in the statistically significant reduction in the incidence, extent and severity of post-surgical adhesions when Haemacure’s fibrin sealant was compared to Interceed(R) Absorbable Adhesion Barrier (Ethicon) and Seprafilm(R) Adhesion Barrier (Genzyme).

A collegue pointed out to me that Angiotech’s CoSeal is being investigated by Baxter for its use as both a sealant and adhesion protection product.

The topic of anti-adhesion has been addressed in prior business reports by MedMarket Diligence, including the February 2007 report and is being addressed in the Report #S175 in process, “Worldwide Surgical Sealants, Glues and Wound Closure Market, 2009-2013.”

Quite a counterintuitive idea to take a glue and use it for anti-adhesion, but the data supports it.

Leave a Reply